-transparent.png){kind=logo}
Auriculin is a potent vasoactive and natriuretic peptide that was recently isolated and purified from rat atrial tissue. Since this peptide could be of great importance for renal, cardiovascular, and volume homeostasis, its functional properties have been characterized in dogs. The effects of synthetic auriculin on renal function, mean blood pressure, plasma renin activity, renin secretory rate, and plasma aldosterone levels were determined. Auriculin was administered intravenously as a prime (1.0 microgram/kg body weight) and constant infusion (0.1 microgram per minute/kg body weight for one hour) to five anesthetized dogs. In addition, two conscious dogs were used to verify some of the results obtained in anesthetized dogs. Auriculin decreased mean blood pressure from 134 +/- 5 to 122 +/- 4 mm Hg (p less than 0.05, paired t test) and increased glomerular filtration rate (25.5 +/- 2.7 to 32.4 +/- 4.1 ml per minute per kidney, p less than 0.05), diuresis (0.21 +/- 0.03 to 1.06 +/- 0.14 ml per minute per kidney, p less than 0.05), natriuresis (38 +/- 0.6 to 187 +/- 35 mueq per minute per kidney, p less than 0.05), and kaliuresis (14.8 +/- 1.6 to 35.7 +/- 6.3 mueq per minute per kidney, p less than 0.05). These effects were sustained throughout the infusion of auriculin and were entirely reversible. Renal plasma flow increased transiently for one to two minutes, and then returned to or below control levels. Urine osmolality decreased by 40 percent (p less than 0.05) whereas free water clearance remained unchanged (p less than 0.05). Auriculin reversibly decreased plasma renin activity (11.6 +/- 2.3 to 3.6 +/- 1.2 ng/ml per hour, p less than 0.05), renin secretory rate (895 +/- 313 to 255 +/- 28 ng per hour per minute, p less than 0.05), and plasma aldosterone levels (8.4 +/- 1.6 to 3.6 +/- 0.7 ng/dl, p less than 0.05), whereas plasma cortisol levels remained unchanged. These results demonstrate that auriculin has a unique combination of functional properties, increasing glomerular filtration rate, diuresis, and natriuresis, without a sustained increase in total renal blood flow, and lowering blood pressure, plasma renin levels, renin secretory rate, and plasma aldosterone levels. These properties suggest an important potential role for atrial natriuretic peptides in the regulation of renal function, extracellular volume, and blood pressure.
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
June 1986,
Federation proceedings,
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
January 1988,
Clinical therapeutics,
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
October 1988,
Hypertension (Dallas, Tex. : 1979),
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
July 1987,
The Tohoku journal of experimental medicine,
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
January 1985,
Hypertension (Dallas, Tex. : 1979),
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
March 1987,
Endocrinology and metabolism clinics of North America,
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
June 1985,
Journal of clinical hypertension,
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
January 1983,
American journal of nephrology,
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
November 1984,
The American journal of physiology,
T Maack, and
D N Marion, and
M J Camargo, and
H D Kleinert, and
J H Laragh, and
E D Vaughan, and
S A Atlas
April 1993,
The Journal of steroid biochemistry and molecular biology,
